Literature DB >> 17329299

Antipsychotic prescribing quality and ethnicity: a study of hospitalized patients in south east London.

Anne Connolly1, Paul Rogers, David Taylor.   

Abstract

A number of studies have shown qualitative and quantitative differences in prescribing of antipsychotics according to patient ethnicity. Black patients tend, for example, to be prescribed higher doses of antipsychotics than whites. Few studies have controlled for other factors which may influence prescribing practice and confound results. This study sought to determine whether or not ethnicity was associated with antipsychotic polypharmacy, high dosage and antipsychotic costs before and after adjustment for potential confounding. We approached inpatients on acute general psychiatry wards at the Maudsley, Bethlem and Lambeth hospitals in south east London. Prescription details were noted. Subjects were interviewed and social and clinical details were recorded. In all, data on 23 potential confounders were collected.A total of 210 patients were approached of whom 153 agreed to take part. Of the 23 potential confounders, only use of English as a first language and duration of illness differed significantly between blacks and whites. Categorical findings were adjusted for these factors and other potential confounders such as age and gender. Total antipsychotic daily dose was 82.2% of licensed maximum in blacks, and 77.2% in whites (p=0.48). Antipsychotic polypharmacy was seen in 23.2% of blacks and 16.9% of whites (adjusted odds ratio (OR) 1.11; 95% CI, 0.45-2.75). High dose (> 100% of maximum dose) antipsychotic regimens were prescribed to 15.9% of blacks and 16.9% of whites (adjusted OR, 0.71: 95% CI, 0.27-1.90). Mean monthly cost of treatment was significantly higher in blacks than whites (182.79 vs 143.08 British pound; p=0.02; adjusted OR (> 150 British pound/month), 2.45: 95% CI, 1.19-5.08). Prescribing quality was similar for blacks and whites. Black ethnicity was associated with significantly higher mean monthly medication costs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329299     DOI: 10.1177/0269881107065899

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  6 in total

Review 1.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

2.  Does race affect prescribing for acute psychosis? Evaluation by a case vignette.

Authors:  Anne Connolly; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

Review 3.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24

4.  Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records.

Authors:  Daniela Fonseca de Freitas; India Patel; Giouliana Kadra-Scalzo; Megan Pritchard; Hitesh Shetty; Matthew Broadbent; Rashmi Patel; Johnny Downs; Aviv Segev; Mizanur Khondoker; James H MacCabe; Kamaldeep Bhui; Richard D Hayes
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2022-03-04       Impact factor: 4.519

5.  Identification of Adverse Drug Events from Free Text Electronic Patient Records and Information in a Large Mental Health Case Register.

Authors:  Ehtesham Iqbal; Robbie Mallah; Richard George Jackson; Michael Ball; Zina M Ibrahim; Matthew Broadbent; Olubanke Dzahini; Robert Stewart; Caroline Johnston; Richard J B Dobson
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

6.  Ethnic minority inequalities in access to treatments for schizophrenia and schizoaffective disorders: findings from a nationally representative cross-sectional study.

Authors:  Jayati Das-Munshi; Dinesh Bhugra; Mike J Crawford
Journal:  BMC Med       Date:  2018-04-18       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.